JAK2 V617F
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F- driven cells and inhibit colony formation of primary MPN cells
... and JAK2 inhibition to enhance the efficacy of targeting MPN cells, the dose of ruxolitinib we utilized in our studies was suboptimal for the effect under investigation ...while JAK2 inhibition in MPN cells ...
17
JAK2 V617F promotes venous thrombosis through β1/β2 integrin activation
... in JAK2-V617F–induced disease, may modulate ICAM1 and VCAM1 expression, we tested HUVECs in response to TNF-α and IL-6 stimulation using flow ...in JAK2-V617F–induced disease increased ICAM1 ...
14
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
... with JAK2 V617F mutation, and with clinical laboratorial data in leukocytes from control, ET and PMF ...involving JAK2 and Src kinases ...the JAK2 V617F allele burden, as well as ...
11
MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 V617F positive primary myelofibrosis
... of JAK2 V617F positive PMF with rapid leukemic evolution, detected a leukemia-specific complex rearrangement in- volving chromosomes 6, 9 and 22 which produced an ab- errant EWSR1-MYB transcription ...
6
<p>Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method</p>
... cells. JAK2 mutation, called JAK2 V617F, is frequently found in Philadelphia chromosome-negative myeloproliferative ...for JAK2 V617F mutation ...for JAK2 V617F were ...
7
Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2 V617F cells
... Given that STAT3 binds to and inhibits Stathmin 1 in non-Hodgkin lymphoma and gastric cancer human cell lines [13, 14], we first confirmed the association of STAT3 and Stathmin 1 in HEL cells, which was abrogated by ...
12
Original Article Chronic neutrophilic leukemia with JAK2 V617F mutation: a case report
... myeloid cells, containing 1.5% bone marrow blasts, 2.5% promyelocytes, and 30% neu- trophilic myelocytes. The cell morphology re- mained normal. Neutrophil alkaline phospha- tase was positive with a score of 300 (Figure ...
6
Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm
... Two children have been described previously with a JAK2-V617F+ MPNs [10]. The first was a six-year-old girl with severe anemia and thrombocytopenia. She was found to have missense mutations in KRAS and ...
5
JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit)
... This case report focuses on a 71-year old patient affected by unknown dyspnea and erythrocytosis referred by his general practitioner to our center for specialist advice after a hema- tological examination had excluded ...
5
A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation
... The JAK2-V617F mutation is one of the major causes of MPNs and is present in the vast majority of these pa- tients (90–95% of PV patients and 50–60% of ET and PMF patients) ...the JAK2-V617F ...
5
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden
... In this study, we attempted to determine whether PegINFα stimulation of the immune system contributes to the beneficial response to PegINFα therapy. PegINFα is a form of INFα with a longer half-life, less toxicity and ...
9
Fahrenkrog-Petersen, Leonie (2018): JAK2 V617F Mutationsanalysen an mikrodissektierten Zellen bei myeloproliferativen Neoplasien. Dissertation, LMU München: Medizinische Fakultät
... Die JAK2 V617F Mutation kann in heterozygoter (ein mutiertes Allel und ein Wildtyp-Allel), homozygoter (2 mutierte Allele) und hemizygoter (ein mutiertes Allel, das andere Allel fehlt) Form ...homozygote ...
108
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
... Hong-Cui Cao et al. compared the different approaches to identify JAK2V617F mutations and introduced PCR– RFLP method as a definite and appropriate way to detect this mutation. Also they use the ARMS PCR and other ...
7
“Study of JAK2 V617F mutation, serum B12 level and interleukin – 23 level in polycythemia vera
... of JAK2 V617F exon 14 has become the first intention diagnostic test to differentiate between PV and erythrocythemic (IE) from erythrocytosis with a sensitivity of 95% and specificity of ...the JAK2 ...
8
The Prevalence of JAK2 -V617F Mutation in Sudanese Patients with Chronic Myeloproliferative Neoplasms
... the JAK2-V617F mutation varied between the MPNs subtypes, it can be found in approximately 95% cases of PV and in approximately 50–60% cases of ET or PMF ...the JAK2-V617F mutation was ...
7
JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?
... a JAK2 V617F mutation while undergoing workup for MPN/ ...The JAK2 V617F mutation has long been de- scribed as dominant gain-of-function mutation that contributes to the expansion of MPN ...of ...
5
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
... Direct oral anticoagulants (DOACs) have largely re- placed VKA in the practical management of many thrombotic events over the past 5 years. They were not used at all in our cohort. Given the small numbers of pa- tients ...
7
The JAK2 V617F Mutation in Chronic Myeloid Leukaemia within a BCR-ABL Positive Cohort of Beninese Patients
... the JAK2 tyrosine kinase gene leading to a substitution of a valine for a phenylalanine (V617F) has been described as the most common form of CML for those who test negative for the Philadelphia (Ph) ...the ...
6
Original Article Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients
... of JAK2 is essential for normal ...in JAK2 deficient mice [10]. JAK2 is composed of two main domains, the first is an enzymatically active kinase domain (JAK homology 1 [JH1]) and a catalytically ...
5
JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia
... the JAK2 V617F mutation was detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome- negative myeloproliferative neoplasms [24], thus suggesting that, ...
13